Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition
NCT00451646
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
75
Enrollment
INDUSTRY
Sponsor class
Conditions
Parenteral Nutrition
Interventions
DRUG:
SMOF lipid and Intralipid
Sponsor
Fresenius Kabi